Skip to main content
DrugPrice

Copay Accumulator

An insurance policy that does not count manufacturer copay assistance toward the patient's annual deductible or out-of-pocket maximum, shifting costs back to the patient once assistance runs out.

How It Works

Copay accumulators (sometimes called "accumulator adjustment programs") emerged around 2018 as an insurer counter to manufacturer copay cards. Under a traditional benefit design, a manufacturer copay card covering a patient's $500/month share of a specialty drug would count toward the patient's $3,000 deductible, exhausting the deductible in about six months, after which the plan pays in full. Under a copay accumulator, only the patient's actual out-of-pocket dollars count toward the deductible, so the manufacturer's payments do not reduce the patient's effective obligation. When the manufacturer card annual maximum is exhausted (typically $5,000-15,000 per patient per year), the patient suddenly faces the full deductible with no assistance, a "copay cliff." The Commonwealth Fund and Patients Rising have documented patients abandoning therapy when hit with unexpected four-figure bills mid-year. As of 2024, roughly 20 states plus DC, Puerto Rico, and the U.S. Virgin Islands have banned copay accumulators for state-regulated plans, including Illinois, Virginia, West Virginia, Connecticut, Arizona, Louisiana, Kentucky, Tennessee, Oklahoma, North Carolina, and New York (limited scope). Self-funded ERISA plans, covering roughly 60% of commercial lives, are largely exempt from state bans. HHS attempted a federal rule via the 2021 Notice of Benefit and Payment Parameters; the rule was struck down in HIV & Hepatitis Policy Institute v. HHS (D.D.C. 2023), and HHS is now in rulemaking for a replacement.

Related Terms

  • Copay Assistance, Financial help from manufacturers, foundations, or pharmacies that reduces a patient's out-of-pocket cost for a specific drug, typically via copay cards, coupons, or charitable grants.
  • Copay Maximizer, A variant of copay accumulator that calibrates the patient copay for a specialty drug to extract the maximum available manufacturer assistance, spreading it across the year.
  • Out-of-Pocket Cost, The amount a patient pays directly for a prescription drug, including copays, coinsurance, and deductible payments.

Explore Drug Data

Most Expensive DrugsGeneric Drug WatchSearch All Drugs

About This Definition

This definition is part of the DrugPrice Drug Pricing Glossary, 49 terms explaining how prescription drug pricing works in the United States. All definitions are written in plain language for patients, caregivers, journalists, and healthcare professionals.

this entity is one of the U.S. Medicare prescription-drug pricing concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the CMS Medicare Part D Drug Spending data data behind every per-entity page on the site.

In the CMS Medicare Part D Drug Spending data data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.

Source: CMS Medicare Part D Spending, 2026.